Read More

Amgen Provides Regulatory Update On Status Of Lumakras; FDA Has Issued New Postmarketing Requirement; LUMAKRAS Dosing Confirmed At 960 mg Once-Daily For Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval

FDA Has Issued New Postmarketing Requirement LUMAKRAS Dosing Confirmed at 960 mg Once-Daily for Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval THOUSAND OAKS, Calif., Dec. 26,

AMGN